Macitentan is a dual-target antagonist of ETA and ETB receptors developed by Actelion, a Swiss company, and was approved by the US FDA in 2013 for treating PAH (Selej et al., 2015). The gene discussed is EDNRA; the disease is pulmonary arterial hypertension.